RU2018140732A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018140732A3 RU2018140732A3 RU2018140732A RU2018140732A RU2018140732A3 RU 2018140732 A3 RU2018140732 A3 RU 2018140732A3 RU 2018140732 A RU2018140732 A RU 2018140732A RU 2018140732 A RU2018140732 A RU 2018140732A RU 2018140732 A3 RU2018140732 A3 RU 2018140732A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329579P | 2016-04-29 | 2016-04-29 | |
| US62/329,579 | 2016-04-29 | ||
| PCT/US2017/029042 WO2017189386A1 (en) | 2016-04-29 | 2017-04-24 | Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018140732A RU2018140732A (ru) | 2020-05-29 |
| RU2018140732A3 true RU2018140732A3 (ru) | 2020-06-02 |
| RU2741911C2 RU2741911C2 (ru) | 2021-01-29 |
Family
ID=60161057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018140732A RU2741911C2 (ru) | 2016-04-29 | 2017-04-24 | Новые замещенные соединения имидазопиридина в качестве ингибиторов индоламин-2,3-диоксигеназы и/или триптофан-2,3-диоксигеназы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11096930B2 (ru) |
| EP (1) | EP3448522B1 (ru) |
| JP (1) | JP6948345B2 (ru) |
| KR (1) | KR102456521B1 (ru) |
| CN (1) | CN109069873B (ru) |
| AU (1) | AU2017257377B2 (ru) |
| BR (1) | BR112018071602B1 (ru) |
| CA (1) | CA3021589A1 (ru) |
| MX (1) | MX380677B (ru) |
| RU (1) | RU2741911C2 (ru) |
| WO (1) | WO2017189386A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668880B1 (en) | 2017-08-17 | 2021-10-06 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| JP7217279B2 (ja) | 2018-01-15 | 2023-02-02 | イドーシア ファーマシューティカルズ リミテッド | インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤 |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| EP3556760A1 (en) * | 2018-04-19 | 2019-10-23 | F. Hoffmann-La Roche AG | Spiro compounds |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| WO2019206800A1 (en) * | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| EP3897622B1 (en) | 2018-12-18 | 2026-01-14 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| US20220259212A1 (en) | 2019-07-11 | 2022-08-18 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| KR102642194B1 (ko) | 2019-10-11 | 2024-03-05 | 삼성전자주식회사 | 전압 컨트롤러 및 이를 포함하는 메모리 장치 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| DK2118101T3 (da) * | 2007-03-09 | 2013-01-02 | Probiodrug Ag | IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer |
| DK2315756T5 (en) * | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
| JP6479476B2 (ja) * | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類 |
| AU2014241079C1 (en) | 2013-03-14 | 2017-07-06 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| PE20151594A1 (es) * | 2013-03-15 | 2015-11-19 | Bristol Myers Squibb Co | Inhibidores de indolamina 2-3 dioxigenasa |
| WO2015082499A2 (en) | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| RU2674027C2 (ru) * | 2014-05-28 | 2018-12-04 | Астразенека Аб | Способ получения AZD5363 (варианты) и применяемое в нем новое промежуточное соединение |
| GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| US20170275302A1 (en) * | 2014-10-14 | 2017-09-28 | Alexander Pasternak | Inhibitors of the renal outer medullary potassium channel |
| JP6701214B2 (ja) | 2014-11-03 | 2020-05-27 | イオメット ファーマ リミテッド | 医薬化合物 |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
-
2017
- 2017-04-24 RU RU2018140732A patent/RU2741911C2/ru active
- 2017-04-24 US US16/088,873 patent/US11096930B2/en active Active
- 2017-04-24 CA CA3021589A patent/CA3021589A1/en active Pending
- 2017-04-24 BR BR112018071602-2A patent/BR112018071602B1/pt active IP Right Grant
- 2017-04-24 MX MX2018013164A patent/MX380677B/es unknown
- 2017-04-24 JP JP2018555971A patent/JP6948345B2/ja not_active Expired - Fee Related
- 2017-04-24 AU AU2017257377A patent/AU2017257377B2/en not_active Ceased
- 2017-04-24 KR KR1020187034045A patent/KR102456521B1/ko active Active
- 2017-04-24 EP EP17790165.9A patent/EP3448522B1/en active Active
- 2017-04-24 WO PCT/US2017/029042 patent/WO2017189386A1/en not_active Ceased
- 2017-04-24 CN CN201780026630.8A patent/CN109069873B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018140732A (ru) | 2020-05-29 |
| BR112018071602B1 (pt) | 2024-02-27 |
| JP6948345B2 (ja) | 2021-10-13 |
| RU2741911C2 (ru) | 2021-01-29 |
| US11096930B2 (en) | 2021-08-24 |
| AU2017257377A1 (en) | 2018-10-11 |
| CA3021589A1 (en) | 2017-11-02 |
| EP3448522B1 (en) | 2021-01-20 |
| MX2018013164A (es) | 2019-06-24 |
| AU2017257377B2 (en) | 2022-06-23 |
| US20200230117A1 (en) | 2020-07-23 |
| MX380677B (es) | 2025-03-12 |
| KR102456521B1 (ko) | 2022-10-20 |
| EP3448522A1 (en) | 2019-03-06 |
| BR112018071602A2 (pt) | 2019-02-12 |
| CN109069873B (zh) | 2021-07-20 |
| WO2017189386A1 (en) | 2017-11-02 |
| CN109069873A (zh) | 2018-12-21 |
| KR20190003619A (ko) | 2019-01-09 |
| EP3448522A4 (en) | 2019-11-27 |
| JP2019515923A (ja) | 2019-06-13 |